BioNTech SE (NASDAQ:BNTX) announced plans today for a clinical trial hub in Taiwan for its MRNA-based cancer immunotherapies. The move comes as part of the company's Asia-Pacific expansion, with the first clinical trial site to be activated to evaluate its candidate treatment against head and neck cancer. At last check, BNTX is off 0.8% at $180.54.
The security has added 42.3% in the last six months, but year-over-year it maintains a hefty 36.1% deficit. Prior to today's pullback, shares had been rallying from a dip to the $118 level, but a new ceiling currently appears to be forming around the $190 region.
Calls are all the rage in the options pits. At the International Securities Exchange (ISE), Cboe Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX), the stock's 50-day put/call volume ratio of 4.66 ranks higher than 99% of readings from the last 12 months, meaning long calls have been getting picked up at a much quicker-than-usual clip.
BioNTech stock sports affordable options at the moment, too. This is per its Schaeffer’s Volatility Index (SVI) of 55%, which ranks in the relatively low 12th percentile of readings from the past 12 months.
Before you make your next trade, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis.
Our team has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and none of the big name stocks were on the list.
They believe these five stocks are the five best companies for investors to buy now...
See The Five Stocks Here
With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.
Get This Free Report
